Literature DB >> 4301509

Enhancing effect of diethylaminoethyl-dextran on the focus-forming titer of a murine sarcoma virus (Harvey strain).

H Duc-Nguyen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4301509      PMCID: PMC375659     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  7 in total

1.  DEAE-dextran: enhancement of cellular transformation induced by avian sarcoma viruses.

Authors:  P K Vogt
Journal:  Virology       Date:  1967-09       Impact factor: 3.616

2.  Infectious poliovirus RNA: a sensitive method of assay.

Authors:  A Vaheri; J S Pagano
Journal:  Virology       Date:  1965-11       Impact factor: 3.616

Review 3.  Plaque mutants of animal viruses.

Authors:  K K Takemoto
Journal:  Prog Med Virol       Date:  1966

4.  Production of altered cell foci in tissue culture by defective Moloney sarcoma virus particles.

Authors:  J W Hartley; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1966-04       Impact factor: 11.205

5.  Enhancement of infectivity of poliovirus RNA with diethylaminoethyl-dextran (DEAE-D).

Authors:  J S Pagano; A Vaheri
Journal:  Arch Gesamte Virusforsch       Date:  1965

6.  Titration patterns of a murine sarcoma-leukemia virus complex: evidence for existence of competent sarcoma virions.

Authors:  T E O'Connor; P J Fischinger
Journal:  Science       Date:  1968-01-19       Impact factor: 47.728

7.  Persistent infection of a rat kidney cell line with Rauscher murine leukemia virus.

Authors:  E N Rosenblum; R F Zeigel
Journal:  J Bacteriol       Date:  1966-10       Impact factor: 3.490

  7 in total
  25 in total

1.  Antigen-specific nonimmunoglobulin factor that neutralizes xenotropic virus is associated with mouse serum lipoproteins.

Authors:  J C Leong; J P Kane; O Oleszko; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

2.  Genetics of xenotropic virus expression in mice. I. Evidence for a single locus regulating spontaneous production of infectious virus in crosses involving NZB/B1NJ and 129/J strains of mice.

Authors:  J A Levy; J Joyner; K T Nayar; R E Kouri
Journal:  J Virol       Date:  1979-06       Impact factor: 5.103

3.  Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera.

Authors:  J A Levy; J N Ihle; O Oleszko; R D Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

4.  FBJ osteosarcoma virus in tissue culture. III. Isolation and characterization of non-virus-producing FBJ-transformed cells.

Authors:  J A Levy; P L Kazan; C A Reilly; M P Finkel
Journal:  J Virol       Date:  1978-04       Impact factor: 5.103

5.  Cationic liposomes (Lipofectin) mediate retroviral infection in the absence of specific receptors.

Authors:  C L Innes; P B Smith; R Langenbach; K R Tindall; L R Boone
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

6.  Increase of retroviral infection in vitro by the binding of antiretroviral antibodies.

Authors:  P Legrain; B Goud; G Buttin
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

7.  An improved syncytia infectivity assay for the bovine leukemia virus.

Authors:  C A Diglio; C E Piper; J F Ferrer
Journal:  In Vitro       Date:  1978-06

8.  Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells.

Authors:  M Tateno; F Gonzalez-Scarano; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.

Authors:  B A Castro; C D Weiss; L D Wiviott; J A Levy
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

10.  Activating and protective capacities of a purified electrophoretic fraction of murine leukemia virus for murine leukemia virus infectivity.

Authors:  P J Fischinger; J Lange; W Schäfer
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.